Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.14 EUR
−18.64 M EUR
0.00 EUR
6.75 M
About Acticor Biotech
Sector
Industry
CEO
Gilles Avenard
Website
Headquarters
Paris
Founded
2013
ISIN
FR0014005OJ5
FIGI
BBG013BTC7K5
Acticor Biotech SAS engages in the research and development of an antithrombotic agent for the treatment of the acute thrombotic diseases. It specializes on ischemic stroke. The company was founded on November 26, 2013 and is headquartered in Paris, France.
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of 7V7 is 0.17 EUR — it has decreased by −27.35% in the past 24 hours. Watch ACTICOR BIOTECH stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange ACTICOR BIOTECH stocks are traded under the ticker 7V7.
7V7 stock is 37.65% volatile and has beta coefficient of 1.35. Track ACTICOR BIOTECH stock price on the chart and check out the list of the most volatile stocks — is ACTICOR BIOTECH there?
Today ACTICOR BIOTECH has the market capitalization of 3.94 M, it has decreased by −13.79% over the last week.
Yes, you can track ACTICOR BIOTECH financials in yearly and quarterly reports right on TradingView.
ACTICOR BIOTECH is going to release the next earnings report on Sep 3, 2025. Keep track of upcoming events with our Earnings Calendar.
7V7 net income for the last half-year is −7.30 M EUR, while the previous report showed −8.56 M EUR of net income which accounts for 14.65% change. Track more ACTICOR BIOTECH financial stats to get the full picture.
No, 7V7 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 13, 2025, the company has 28.00 employees. See our rating of the largest employees — is ACTICOR BIOTECH on this list?
Like other stocks, 7V7 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ACTICOR BIOTECH stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ACTICOR BIOTECH technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ACTICOR BIOTECH stock shows the sell signal. See more of ACTICOR BIOTECH technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.